<DOC>
	<DOCNO>NCT01285232</DOCNO>
	<brief_summary>Rationale : Once diabetes develops , β-cell function progressively deteriorate therapeutic approach prevent delay loss β-cell function need treatment type 2 diabetes mellitus . Recent finding suggest interleukin-1 ( IL-1 ) may involve progressive β-cell dysfunction type 2 diabetes mellitus . Objective : determine whether block IL-1β recombinant human IL-1ra ( anakinra ) improve beta-cell function subject β-cell dysfunction .</brief_summary>
	<brief_title>The Effect Anakinra Insulin Secretion</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Impaired glucose tolerance assessed oral glucose tolerance test and/or impair fast glucose ( ≥ 5.6 mmol/L ) and/or HbA1c level 5.76.4 % BMI &gt; 25 kg/m2 Age 4070 year Known diabetes mellitus Fasting plasma glucose ≥ 7.0 mmol/L HbA1c ≥ 6.5 % Immunodeficiency immunosuppressive treatment ( include TNFα block agent corticosteroid ) Use antiinflammatory drug ( include corticosteroid non steroidal antiinflammatory drug , 100 mg less aspirin allow ) Signs current infection ( fever , Creactive protein &gt; 30 mmol/L , treatment antibiotic , previous current diagnosis tuberculosis ) A history recurrent infection Pregnancy breastfeeding ( contraception least 3 month inclusion require ) Liver disease define aspartate aminotransferase alanine aminotransferase level three time upper limit normal range Renal disease define MDRD &lt; 60 ml/min/1.73m2 Neutropenia &lt; 2x 109/L Inability understand nature extent trial procedure require . Any medical condition might interfere current study protocol Participation drug trial within 60 day prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>